Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2010
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an intelligent robotic radiosurgery system used to treat solid tumors anywhere in the body. As of June 30, 2010, 206 systems were installed globally (132 in the Americas, 45 in Asia, 29 in Europe). The company generates revenue through system sales, service contracts, and a shared ownership program.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 | Fiscal 2008 |
|---|---|---|---|
| Net Revenue | $221.6 million | $233.6 million | $210.4 million |
| Gross Profit | $104.0 million | $115.3 million | $107.0 million |
| Gross Margin | 46.9% | 49.4% | 50.8% |
| Operating Income | $2.8 million | ($2.4 million) | ($0.9 million) |
| Net Income | $2.8 million | $0.6 million | $5.4 million |
| Cash and Cash Equivalents | $45.4 million | $36.8 million | $36.9 million |
| Short-term Investments | $99.9 million | $64.6 million | $85.5 million |
| Working Capital | $152.0 million | $80.1 million | $87.7 million |
| Debt | $0 | $0 | $0 |
Note: The company had no outstanding borrowings as of June 30, 2010.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by $12.0 million (5.1%) compared to fiscal 2009. This was primarily due to a decrease in product revenue ($18.0 million) and shared ownership program revenue ($1.8 million), partially offset by an increase in service revenue ($11.2 million).
- Installation Volume: The company installed 31 CyberKnife systems in fiscal 2010, down from 36 systems in fiscal 2009.
- Profitability Improvement: Despite lower revenue, the company returned to profitability with $2.8 million in net income, compared to $0.6 million in fiscal 2009. Operating income improved from a loss of $2.4 million to a profit of $2.8 million.
- Expense Reduction: Selling and marketing expenses decreased by $11.3 million (24.8%) due to headcount reductions and spending controls. Research and development expenses decreased by $4.5 million (12.4%).
- Platinum Plan Recognition: The company recognized $28.9 million of revenue in fiscal 2010 from legacy Platinum service plans after satisfying all upgrade obligations. This is a one-time recognition event as the company has fulfilled obligations on all such units.
Guidance, Outlook, and Risks
Strategic Alliance: In June 2010, Accuray entered into a Strategic Alliance Agreement with Siemens AG. This agreement grants Siemens distribution rights for the CyberKnife system in multi-product sales and establishes a research and development relationship. No payments had been earned from this alliance as of June 30, 2010.
Backlog: As of June 30, 2010, backlog was approximately $374.1 million (under a refined definition), consisting of $131.9 million in system sales and $242.2 million in service plans. The company anticipates recognizing this backlog over the next five years.
Key Risks and Contingencies:
- Reimbursement Uncertainty: Proposed Medicare rate changes for 2011 include a 4.4% decrease for the first treatment code (G0339). The company notes that reimbursement uncertainty has complicated customer decision-making.
- Legal Proceedings: The company is subject to consolidated securities class action lawsuits and shareholder derivative lawsuits alleging false statements regarding operations. Additionally, Best Medical International filed a patent infringement lawsuit in August 2010. No liabilities have been recorded as losses are not considered probable or estimable.
- Supply Chain: The company relies on single-source suppliers for critical components (e.g., robotic manipulator, magnetron). Disruptions could delay shipments.
- Regulatory: Future product upgrades may require new FDA 510(k) clearances, which could delay market introduction.
Investor Verification Checklist
- Revenue Recognition Timing: Verify the impact of the "Platinum" legacy service plan revenue recognition ($28.9 million in 2010) on the comparability of year-over-year results.
- Backlog Conversion: Monitor the conversion rate of the $374.1 million backlog into recognized revenue, noting the company's warning that backlog does not guarantee future revenue due to cancellations or regulatory delays.
- Siemens Alliance Execution: Track the progress of the Siemens strategic alliance, specifically the development of "Cayman Products" and the realization of distribution revenue.
- Reimbursement Rates: Confirm the finalization of 2011 Medicare reimbursement rates and their potential impact on hospital purchasing decisions.
- Legal Exposure: Review the status of the securities class action and patent infringement lawsuits for any updates on potential financial impact.